Oct 7 (Reuters) - Bristol-Myers Squibb (NYSE:BMY) Co BMY.N :
* HEALTH CANADA APPROVES ZEPOSIA®, AN ORAL TREATMENT FOR RELAPSING REMITTING MULTIPLE SCLEROSIS
* BRISTOL-MYERS SQUIBB - HEALTH CANADA APPROVAL IS BASED ON DATA FROM RANDOMIZED, ACTIVE-CONTROLLED PHASE 3 SUNBEAM AND RADIANCE PART B CLINICAL TRIALS